Xanthine
- Generic Name
- Xanthine
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4N4O2
- CAS Number
- 69-89-6
- Unique Ingredient Identifier
- 1AVZ07U9S7
- Background
A purine base found in most body tissues and fluids, certain plants, and some urinary calculi. It is an intermediate in the degradation of adenosine monophosphate to uric acid, being formed by oxidation of hypoxanthine. The methylated xanthine compounds caffeine, theobromine, and theophylline and their derivatives are used in medicine for their bronchodilator effects. (Dorland, 28th ed)
- Associated Conditions
- Uncomplicated hepatic dysfunction
Shanton's SAP-001 Shows Breakthrough Results in Refractory Gout Phase 2b Trial
• Shanton Pharma's investigational drug SAP-001 demonstrated nearly 100% efficacy in lowering serum uric acid levels below 6mg/dL in refractory gout patients after 3 months, compared to only 10% with conventional therapy.
• The novel first-in-class oral medication targets a distinct kidney transporter, offering a potential paradigm shift for refractory gout patients who currently require intravenous uricase treatments.
• With an excellent safety profile and sustained efficacy through 6 months of treatment, Shanton plans to advance SAP-001 to pivotal studies later this year to address significant unmet needs in gout management.
Shanton Pharma Completes Enrollment for Phase 2b Trial of SAP-001 in Refractory Gout
• Shanton Pharma has completed enrollment of 87 patients across 21 US sites for its Phase 2b study of SAP-001, a potential breakthrough treatment for refractory and tophaceous gout.
• The six-month clinical trial targets patients who don't respond to maximum tolerable doses of conventional Xanthine Oxidase Inhibitors, with topline data expected in Q1 2025.
• SAP-001, designed for once-daily oral administration, demonstrated promising efficacy and safety in earlier Phase 1 and 2a studies, positioning it as a potential best-in-class treatment for severe gout.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath